AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12949664 — intervention group
Group type: EXPERIMENTAL
Intervention: Vozraston
Number of subjects: 34
Study 12949664 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 34
Study 10978253 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (182 mg of RRR‐alpha‐tocopherol acetate per day)
Number of subjects: 48
Study 10978253 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg of slow release ascorbate per day)
Number of subjects: 48
Study 10978253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and C
Number of subjects: 48
Study 10978253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8774056 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 38
Study 8774056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 1346413 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (300 mg twice daily)
Number of subjects: 84
Study 1346413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 1346413 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 84
Study 6593316 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 rad X 18 cranial radiation therapy
Number of subjects: 97
Study 6593316 — intervention group
Group type: COMPARATOR
Intervention: 180 rad X 10 cranial radiation therapy
Number of subjects: 97
Study 30885073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (one dose)
Number of subjects: 0
Study 30885073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, gentamicin, and clindamycin (AGC-1, one-time intravenous dose)
Number of subjects: 0
Study 30885073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, gentamicin, and clindamycin (AGC-24, 24-hour coverage)
Number of subjects: 0
Study 30885073 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 0
Study 29477099 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable offloading device
Number of subjects: 31
Study 29477099 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable offloading device (adherent patients)
Number of subjects: 31
Study 27234302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Internet Intervention
Number of subjects: 205
Study 27234302 — intervention group
Group type: COMPARATOR
Intervention: Wellness Contact Control Internet Group
Number of subjects: 205
Study 25697490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection text messages
Number of subjects: 546
Study 25697490 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin self-examination text messages
Number of subjects: 546
Study 25697490 — intervention group
Group type: COMPARATOR
Intervention: Attention-control text messages
Number of subjects: 546
Study 23067340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac ultrasound (ICE) imaging
Number of subjects: 50
Study 23067340 — intervention group
Group type: COMPARATOR
Intervention: Traditional electroanatomic mapping
Number of subjects: 50
Study 23067340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation energy delivery outside the greatest esophagus anatomy borders
Number of subjects: 50
Study 23067340 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 12 months
Number of subjects: 50
Study 23067340 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ablation observation
Number of subjects: 50
Study 20664838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with beta‐tricalcium phosphate (b‐TCP)
Number of subjects: 12
Study 20664838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with collagen containing anorganic deproteinized bovine bone (xenograft)
Number of subjects: 12
Study 20664838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL recombinant human platelet‐derived growth factor (rhPDGF‐BB) with either b‐TCP or xenograft
Number of subjects: 12
Study 18248280 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-level lumbar arthroplasty (Charité Artificial Disc)
Number of subjects: 276
Study 16877370 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole and FSH
Number of subjects: 432
Study 16877370 — intervention group
Group type: COMPARATOR
Intervention: FSH only
Number of subjects: 432
Study 14499772 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, clarithromycin, and amoxicillin (LCA)
Number of subjects: 157
Study 14499772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 10655965 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA (1.05 g EPA plus 0.55 g DHA)
Number of subjects: 50
Study 10655965 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (6.8 g/d)
Number of subjects: 50
Study 10655965 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (diet during run-in period)
Number of subjects: 50
Study 9101884 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 0
Study 9101884 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 0
Study 2065506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection (1 or 2 knees)
Number of subjects: 20
Study 6132218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue liquid supplement
Number of subjects: 28
Study 6132218 — intervention group
Group type: COMPARATOR
Intervention: Ordinary diet
Number of subjects: 28
Study 4065108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic/Circuit Weight Training (A/CWT) for 10 weeks at 60% of 1RM
Number of subjects: 137
Study 4065108 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic/Circuit Weight Training at 70% of 1RM (A/CWT-70)
Number of subjects: 137
Study 4065108 — intervention group
Group type: COMPARATOR
Intervention: Aerobic/Circuit Weight Training at 40% of 1RM (A/CWT-40)
Number of subjects: 137
Study 4065108 — intervention group
Group type: COMPARATOR
Intervention: Standard Navy Aerobic/Calisthenic Training (A/CAL)
Number of subjects: 137
Study 30572864 — intervention group
Group type: COMPARATOR
Intervention: Unhealthy food sponsorship
Number of subjects: 1132
Study 30572864 — intervention group
Group type: COMPARATOR
Intervention: Healthier food sponsorship
Number of subjects: 1132
Study 30572864 — intervention group
Group type: COMPARATOR
Intervention: Obesity prevention campaign sponsorship
Number of subjects: 1132
Study 26490126 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored group (dETCO2 monitoring)
Number of subjects: 55
Study 26490126 — intervention group
Group type: COMPARATOR
Intervention: Masked group (no dETCO2 monitoring)
Number of subjects: 55
Study 24164904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (5 or 10 mg for low-weight cohort; 10 or 20 mg for high-weight cohort)
Number of subjects: 90
Study 22389273 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet with eicosapentaenoic acid‐enriched supplementation for 7 days before surgery and for 21 days after surgery
Number of subjects: 0
Study 22389273 — intervention group
Group type: COMPARATOR
Intervention: No supplementation with oral nutrients (standard diet)
Number of subjects: 0
Study 22389273 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet with eicosapentaenoic acid‐enriched supplementation
Number of subjects: 0
Study 20159179 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 58
Study 20159179 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon ablation (TBA)
Number of subjects: 58
Study 18398307 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Chick Embryo Cell Vaccine (PCECV) administered as a three-dose regimen (1.0 mL or 0.5 mL)
Number of subjects: 175
Study 18398307 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine (PVRV) administered as a three-dose regimen (0.5 mL)
Number of subjects: 175
Study 15718046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients with cognitive impairment (VaD and VCI)
Number of subjects: 48
Study 15718046 — intervention group
Group type: COMPARATOR
Intervention: Stroke patients without cognitive impairment
Number of subjects: 48
Study 15718046 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly controls
Number of subjects: 48
Study 14728348 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized menopause decision support aid (DSA)
Number of subjects: 0
Study 14728348 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10912985 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine‐prilocaine
Number of subjects: 61
Study 10912985 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% lidocaine
Number of subjects: 61
Study 10912985 — intervention group
Group type: COMPARATOR
Intervention: Control (acid‐mantle cream)
Number of subjects: 61
Study 9072226 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 0
Study 9072226 — intervention group
Group type: COMPARATOR
Intervention: No administration of T3
Number of subjects: 0
Study 1984366 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% bupivacaine with 1:200,000 epinephrine through the single catheter
Number of subjects: 20
Study 1984366 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of 0.5% bupivacaine with or without 1:200,000 epinephrine through each of the two catheters
Number of subjects: 20
Study 6407054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg (an anxiolytic 1,5‐benzodiazepine derivative)
Number of subjects: 0
Study 6407054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31047670 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune interventions
Number of subjects: 0
Study 31047670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27852952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐level positive airway pressure (PAP)
Number of subjects: 60
Study 27852952 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airways pressure (CPAP)
Number of subjects: 60
Study 27852952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐level PAP
Number of subjects: 60
Study 27852952 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 60
Study 26095194 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml 0.25% bupivacaine (Group B)
Number of subjects: 110
Study 26095194 — intervention group
Group type: COMPARATOR
Intervention: 1.5 ml saline (Group S)
Number of subjects: 110
Study 23775574 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 23775574 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 40
Study 21450662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based training
Number of subjects: 60
Study 21450662 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training
Number of subjects: 60
Study 21450662 — intervention group
Group type: COMPARATOR
Intervention: Home training and Hospital training
Number of subjects: 60
Study 19660507 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose drink
Number of subjects: 0
Study 19660507 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 16701989 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily budesonide/formoterol (80/4.5 microg, 2 inhalations in the evening)
Number of subjects: 617
Study 16701989 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily budesonide/formoterol (80/4.5 microg, 1 inhalation)
Number of subjects: 617
Study 16701989 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (200 microg, 1 inhalation in the evening)
Number of subjects: 617
Study 16701989 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol therapy
Number of subjects: 617
Study 15243815 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (specifics not provided)
Number of subjects: 0
Study 15243815 — intervention group
Group type: EXPERIMENTAL
Intervention: C(6) antibody testing
Number of subjects: 0
Study 11345361 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogen daily for three months
Number of subjects: 55
Study 9786353 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogranin positivity (neuroendocrine cell expression)
Number of subjects: 48
Study 9786353 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cancer-free survival
Number of subjects: 48
Study 9786353 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of chromogranin positivity with survival
Number of subjects: 48
Study 7603732 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mmol of magnesium
Number of subjects: 0
Study 7603732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3044484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine prophylaxis (3 peri-operative doses)
Number of subjects: 243
Study 3044484 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 243
Study 31796208 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2332
Study 31796208 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2332
Study 31307948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) plus Rilpivirine (25 mg) orally once daily (early-switch group)
Number of subjects: 1024
Study 31307948 — intervention group
Group type: COMPARATOR
Intervention: Standard ART regimen (late-switch group)
Number of subjects: 1024
Study 31307948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Rilpivirine (early-switch group)
Number of subjects: 1024
Study 28105994 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐SES
Number of subjects: 372
Study 28105994 — intervention group
Group type: COMPARATOR
Intervention: R‐ZES
Number of subjects: 372
Study 24671714 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine-containing toothpaste (Theodent-classic-F®)
Number of subjects: 80
Study 24671714 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine-containing toothpaste (Theodent-classic®)
Number of subjects: 80
Study 24671714 — intervention group
Group type: EXPERIMENTAL
Intervention: Novamin®-containing toothpaste (Sensodyne®-5000-Nupro)
Number of subjects: 80
Study 24671714 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste (Colgate®-Regular)
Number of subjects: 80
Study 23067311 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg GSK1144814
Number of subjects: 20
Study 23067311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 22136026 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp and body acupuncture (group B)
Number of subjects: 20
Study 22136026 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture (group A)
Number of subjects: 20
Study 19840020 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDChT) with autologous stem cell support (ASCS)
Number of subjects: 0
Study 19840020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential HD regimen with one or two conventional chemotherapy cycles followed by two or three HD cycles of CE
Number of subjects: 0
Study 19840020 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDChT)
Number of subjects: 0
Study 19840020 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy
Number of subjects: 0
Study 16998274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil hydrochloride (30 mg by intravenous injection over 30 minutes three times a day for 14 days)
Number of subjects: 72
Study 16998274 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (1 mg/hr by continuous intravenous infusion for 14 days)
Number of subjects: 72
Study 16998274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil hydrochloride
Number of subjects: 72
Study 16998274 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 72
Study 14714931 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety, Depression, and Mood Scale (ADAMS)
Number of subjects: 129
Study 14714931 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAMS
Number of subjects: 129
Study 11097664 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-gauge epidural catheter through a 19-gauge Tuohy needle (Group EC)
Number of subjects: 90
Study 11097664 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-gauge microcatheter through a 22-gauge spinal needle (Group MC)
Number of subjects: 90
Study 11097664 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge spinal catheter over a 27-gauge spinal needle through an epidurally placed 18-gauge Crawford needle (Group SC)
Number of subjects: 90
Study 11097664 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 9494056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program including a low-fat diet and weekly moderate exercise (Experimental group, N = 27)
Number of subjects: 56
Study 9494056 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group, N = 29)
Number of subjects: 56
Study 9494056 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (N = 27)
Number of subjects: 56
Study 8342838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 21
Study 8342838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8342838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (Clonidine and Placebo)
Number of subjects: 21
Study 3668249 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-selective agent) with or without diuretics and/or vasodilators
Number of subjects: 939
Study 3668249 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol treatment
Number of subjects: 939
Study 31617235 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/d
Number of subjects: 0
Study 31617235 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/d
Number of subjects: 0
Study 31617235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31617235 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (combined doses)
Number of subjects: 0
Study 29225012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided out-of-plane application
Number of subjects: 60
Study 29225012 — intervention group
Group type: COMPARATOR
Intervention: Traditional landmark method
Number of subjects: 60
Study 29225012 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography-guided in-plane application
Number of subjects: 60
Study 27465375 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 128
Study 27465375 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 128
Study 24015934 — intervention group
Group type: EXPERIMENTAL
Intervention: NEURO (low-frequency repetitive transcranial magnetic stimulation plus occupational therapy)
Number of subjects: 66
Study 24015934 — intervention group
Group type: COMPARATOR
Intervention: constraint-induced movement therapy
Number of subjects: 66
Study 22446665 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training group (WBVG)
Number of subjects: 23
Study 20449588 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI follow-up after free tendon graft reconstruction
Number of subjects: 10
Study 18234328 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly‐Lactide‐co‐Glycolide (PLG) polymer (Fisiograft)
Number of subjects: 19
Study 18234328 — intervention group
Group type: COMPARATOR
Intervention: Platelet‐rich plasma (PRP)
Number of subjects: 19
Study 18234328 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone (AB)
Number of subjects: 19
Study 15826612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian networks
Number of subjects: 0
Study 15826612 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristic features
Number of subjects: 0
Study 12814142 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) 1 mg/kg/day (weight < 75 kg = 50 mg/day; weight ≥ 75 kg = 100 mg/day)
Number of subjects: 81
Study 12814142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 12814142 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB)
Number of subjects: 81
Study 10824899 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Fontan procedure
Number of subjects: 55
Study 10824899 — intervention group
Group type: EXPERIMENTAL
Intervention: Senning operation
Number of subjects: 55
Study 10824899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 10824899 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 55
Study 8684391 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS) during a 3-week home-based gait-training program
Number of subjects: 15
Study 8684391 — intervention group
Group type: COMPARATOR
Intervention: Self-paced training (control group)
Number of subjects: 15
Study 8684391 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 15
Study 8684391 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Number of subjects: 15
Study 8435168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 51
Study 8435168 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 51
Study 3316172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 9
Study 3316172 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 9
Study 29169952 — intervention group
Group type: EXPERIMENTAL
Intervention: VREMS (Virtual Reality Epley Maneuver System)
Number of subjects: 20
Study 29169952 — intervention group
Group type: COMPARATOR
Intervention: Instructional Handout (IH)
Number of subjects: 20
Study 29169952 — intervention group
Group type: EXPERIMENTAL
Intervention: VREMS
Number of subjects: 20
Study 29169952 — intervention group
Group type: EXPERIMENTAL
Intervention: NASA Task Load Index (TLX)
Number of subjects: 20